Lilly Acquires Three Companies for Up to $2.28B to Enter Infectious Disease Vaccine Market
LLY sits 74% above its 52-week low of $623.78.
Summary
Eli Lilly announced the acquisition of three companies: Curevo, LimmaTech Biologics, and Vaccine Company. The deals are valued at up to $1.5 billion for Curevo and up to $780 million for LimmaTech Biologics, with the third acquisition's terms not fully detailed. This strategic move expands Lilly's R&D into infectious diseases, focusing on vaccines for viral and bacterial pathogens linked to long-term health risks and antimicrobial resistance. This follows a period of aggressive M&A for Lilly, including a $6.3 billion acquisition in early April and a $1.1 billion acquisition mentioned in its Q1 2026 report, demonstrating continued strategic expansion. The investment signals a long-term commitment to prevention strategies in a new therapeutic area.
At the time of this announcement, LLY was trading at $1,082.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1T. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.